Showing results (71-80 of 108) with videos related to
Sort By:
Pageof 11
Signal Transduction and Targeted Therapy|July 23, 2026
Mechanisms and therapeutic targets in distant metastasis of lung adenocarcinomaTongji Xie, Lige Wu, Yan Li, et al.Journal of Hematology & Oncology|January 18, 2020
First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancerXingsheng Hu, Xin Zheng, Sheng Yang, et al.Thoracic Cancer|October 19, 2020
Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIsLu Yang, Xuezhi Hao, Xingsheng Hu, et al.Cancer Biology & Medicine|May 7, 2021
The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasmsHuihui Yin, Lu Yang, Gongxin Peng, et al.Thoracic Cancer|October 17, 2018
Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancerPuyuan Xing, Yuxin Mu, Yan Wang, et al.Thoracic Cancer|May 17, 2018
Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancerPuyuan Xing, Yuxin Mu, Yan Wang, et al.Signal Transduction and Targeted Therapy|October 1, 2024
Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomasYan Li, Tongji Xie, Shouzheng Wang, et al.BMC Medicine|January 18, 2022
Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective studyZihua Zou, Puyuan Xing, Xuezhi Hao, et al.Cancer Medicine|May 24, 2022
First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from ChinaGuangjian Yang, Yaning Yang, Runze Liu, et al.Thoracic Cancer|February 8, 2018
Heterogeneity-based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case reportYutao Liu, Xuezhi Hao, Xingsheng Hu, et al.Pageof 11